Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Using a Pharmacology to Payer Framework to Support Product Development

Modeling and simulation (M&S) of complex systems has primarily advanced vertically in differing scientific domains with a variety of domain-specific approaches and applications. The pharmacology to payer (P2P) concept is a way to connect independent domains to address drug development market failures. As an initial proof of concept, we collaborated with a team of clinical pharmacologists, […]

Author(s): Carl Kirkpatrick, Craig Rayner
Solution: Clinical Pharmacology Strategy
Therapeutic Area: Infectious Disease
More Info

Certara and Faculty from UNC Eshelman School of Pharmacy to Launch New Pharmacometrics Skills Competition at ASCPT 2018 Annual Meeting

PRINCETON, NJ – Mar. 12, 2018 – Certara today announced that it is partnering with faculty at the UNC Eshelman School of Pharmacy to launch the Model-informed Drug Development (MIDD) Gran Prix at the 2018 American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting.

Solution: Clinical Pharmacology Strategy, Model-based Meta-analysis, PBPK Modeling & Simulation, PK/PD Modeling & Simulation, Systems Pharmacology
Therapeutic Area: Infectious Disease, Pediatrics
More Info

How to Plan and Implement a Pharmacology to Payer Framework

Pharmacology to the payer (P2P) is an innovative approach to create a framework for dialogue between drug sponsors, regulators, and payers. The core structure is the sequential linking of quantitative mathematical models—pharmacology, pharmacokinetics/pharmacodynamics (PK/PD), disease progression, epidemiology, health utilization, and health economics. In this blog post, we discuss how working with an amazing team of […]

Author(s): Carl Kirkpatrick and Craig Rayner
Solution: Clinical Pharmacology Strategy
Therapeutic Area: Infectious Disease
More Info

Pharmacology to Payer: One Quantitative Drug Development Framework to Rule Them All

In JRR Tolkien’s Lord of the Rings, the power of the one ring forged by the evil sorcerer, Sauron, is used to control all of the disaggregated, independent kingdoms of Middle Earth. Similarly, but without the malice, the “pharmacology to the payer” (P2P) quantitative framework can be viewed as a way to unite and connect […]

Author(s): Craig Rayner
Solution: Clinical Pharmacology Strategy
Therapeutic Area: Infectious Disease
More Info

Using Model-based Meta-analysis to Inform Drug Development for Autoimmune Diseases

MBMA helps sponsors design less costly and more precise trials with an eye toward achieving commercial success for both the drug and portfolio. Watch this webinar with Dr. Mark Lovern, Vice President at Certara Strategic Consulting, to learn how leveraging public data can provide value by abbreviating the “cash spiral” inherent to proprietary data.

Speaker(s): Mark Lovern
Solution: Model-based Meta-analysis, PK/PD Modeling & Simulation
More Info

Best Practices in Clinical Pharmacology Gap Analysis

Watch this webinar to learn from Dr. Julie Bullock, Senior Director of Consulting Services at Certara, how gap analysis can help you ensure that your development program will contain all the elements needed to satisfy regulators and investors during all phases of drug development from IND to NDA.

Speaker(s): Julie Bullock
Solution: Clinical Pharmacology Strategy
More Info
Learn More LinkedIn Twitter Facebook Email